Robert J. Shovlin's most recent trade in Neogenomics Inc. was a trade of 130,604 Common Stock done at an average price of $39.3 . Disclosure was reported to the exchange on May 25, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Sale of securities on an exchange or to another person at price $ 39.31 per share. | 25 May 2021 | 130,604 | 150,101 (0%) | 0% | 39.3 | 5,134,043 | Common Stock |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 96,167 | 0 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.03 per share. | 25 May 2021 | 96,167 | 249,914 (0%) | 0% | 8.0 | 772,221 | Common Stock |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 16,724 | 33,449 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.60 per share. | 25 May 2021 | 16,724 | 266,638 (0%) | 0% | 19.6 | 327,790 | Common Stock |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.33 per share. | 25 May 2021 | 14,067 | 280,705 (0%) | 0% | 28.3 | 398,518 | Common Stock |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 14,067 | 42,204 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 38,688 | 38,688 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 6,827 | 153,747 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 742 | 147,528 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Robert J. Shovlin | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Mar 2021 | 608 | 146,920 (0%) | 0% | 0 | Common Stock |